Seed topic: thrombosis (blood clots) and related cardiovascular and cerebrovascular events.
Thrombosis refers to the formation of blood clots (thrombi) within blood vessels, which can obstruct flow and cause serious outcomes such as deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, myocardial infarction (heart attack), and other forms of arterial or venous occlusion. The clinical relationship between thrombosis and major triggers is complex and depends on clot type, patient risk factors (age, immobility, malignancy, inherited or acquired hypercoagulable states), and the presence of inflammation or endothelial injury. In the context of COVID-19 and COVID-19 vaccination, public health guidance emphasizes that most people do not develop thrombosis from vaccination; however, specific rare clotting syndromes have been recognized and studied.
One key phenomenon is vaccine-induced immune thrombotic thrombocytopenia (VITT), also described as an immune-mediated thrombosis syndrome. VITT is characterized by (1) thrombosis occurring at unusual sites (such as cerebral venous sinus thrombosis or splanchnic vein thrombosis), (2) thrombocytopenia (low platelet count), and (3) evidence of platelet-activating antibodies. The mechanism is thought to resemble heparin-induced thrombocytopenia (HIT): antibodies bind to platelet factor 4 (PF4), leading to platelet activation, thrombin generation, and widespread clotting. Importantly, VITT has been reported most often after certain adenoviral vector vaccines, typically with onset in the range of roughly 4 to 28 days after vaccination.
Separately, thromboembolic risk is strongly influenced by COVID-19 infection itself. Acute infection can produce a hypercoagulable state through systemic inflammation, cytokine-driven endothelial dysfunction, increased tissue factor expression, and impaired fibrinolysis. These processes raise the probability of DVT/PE and arterial events, and they can worsen pre-existing cardiovascular disease. Therefore, when considering whether thrombosis is “normal” after a given age or after vaccination, it is critical to separate baseline age-related risk from event-specific risk attributable to vaccination. Baseline risk increases with age because vascular biology changes over time: endothelial function declines, atherosclerosis progresses, and comorbidities accumulate. Yet labeling age-related risks as “normal” can obscure the need for risk stratification and evaluation of red-flag symptoms.
Pulmonary embolism occurs when a clot travels to the pulmonary arterial circulation, producing ventilation-perfusion mismatch, hypoxemia, right ventricular strain, and in severe cases obstructive shock. Clinically, PE can present with sudden dyspnea, pleuritic chest pain, hemoptysis, syncope, tachycardia, and sometimes leg swelling if DVT coexists. Stroke arises when cerebral arteries become occluded by thrombosis (in-situ) or emboli; symptoms include sudden unilateral weakness, speech or vision disturbance, and acute severe headache in some subtypes such as cerebral venous thrombosis.
Myocardial infarction results from reduced coronary blood flow due to plaque rupture and thrombosis in most cases. The pathways overlap with those that promote thrombosis—platelet activation, coagulation cascade amplification, inflammation, and endothelial injury. In older adults, a higher prevalence of atherosclerotic disease and cardiovascular risk factors (hypertension, diabetes, dyslipidemia, smoking, atrial fibrillation) increases absolute MI and stroke risk independent of vaccination.
For vaccine safety monitoring, large-scale observational studies and pharmacovigilance analyses compare expected event rates in vaccinated versus unvaccinated periods and across demographic strata. These studies have identified that serious thrombosis events remain rare. When VITT occurs, healthcare systems have developed protocols emphasizing prompt diagnosis and treatment. The clinical approach typically involves obtaining platelet counts, D-dimer levels, coagulation parameters, and imaging tailored to suspected clot location. Therapeutic strategies may include non-heparin anticoagulation, intravenous immunoglobulin (IVIG) to reduce antibody-mediated platelet activation, and avoidance of platelet transfusions unless life-threatening bleeding is present.
To reconcile public concern with evidence-based risk communication, clinicians distinguish between (a) common age-associated risk and (b) rare immune-mediated adverse events. The latter is not “normal” and should trigger medical assessment. At the same time, it is misleading to imply that vaccination broadly causes heart attacks, strokes, or pulmonary embolisms in general. The most substantial population-level driver of increased thrombotic events has been COVID-19 infection and its complications, while VITT represents a rare, well-characterized syndrome with specific features and time windows.
If an individual has concerning symptoms after vaccination—such as severe headache, visual changes, shortness of breath, chest pain, leg swelling, or neurologic deficits—they should seek urgent medical care rather than assume the event is expected. Early evaluation enables imaging, laboratory confirmation, and timely treatment, which can be life-saving.
Overall, thrombosis risk is multifactorial. Age and comorbidities increase baseline risk, COVID-19 infection increases thrombotic risk through inflammatory and coagulation pathways, and vaccination—while generally safe—has been associated with a rare immune-mediated clotting syndrome in a defined time frame and with characteristic laboratory findings. Source: [ABridgen]
Andrew Bridgen: Are the MSM trying to programme us to accept that blood clots resulting in strokes, pulmonary embolisms and heart attacks are normal after 40 ? Is this because heart attack ,stroke and pulmonary embolism risk is increased after Covid vaccination ?. #breaking
— @ABridgen May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
